Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)
NCT04030455Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in laryngeal squamous cell carcinoma (LSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT04030455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030455.